Moreover, compelling evidence from experimental models has underscored the therapeutic potential of selective PTGS2 inhibitors such as celecoxib in impeding gastric tumor development, offering promising avenues for targeted intervention strategies in the realm of gastric cancer therapeutics [36]. This evidence concerns the gene PTGS2 and gastric neoplasm.